HENWOOD GERALDINE 4/A
4/A · Recro Pharma, Inc. · Filed Apr 20, 2020
Insider Transaction Report
Form 4/AAmended
HENWOOD GERALDINE
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2020-04-17$2.47/sh+80,000$197,600→ 321,194 total - Sale
Common Stock
2020-04-17$8.22/sh−80,000$657,600→ 241,194 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-04-17−80,000Exercise: $2.47Exp: 2024-12-16→ Common Stock (80,000 underlying)
Holdings
- 50,000(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]This amended Form 4 is being filed to reflect an exercise of options that occurred on the same day as the transaction.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.51, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
- [F4]The shares subject to this option are fully vested and exercisable.